Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors
NCT05944185Phase 2Not yet recruiting
- Sponsor
- Shanghai Cell Therapy Group
- Start
- Sep 2023
- Primary completion
- Sep 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BZD1901 in solid tumor (advanced stage), sponsored by Shanghai Cell Therapy Group. Primary endpoints: Incidence of Treatment Related Adverse Events at 12 months, Maximum Tolerated Dose at 28 days and 1 more. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
BZD1901
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05944185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05944185.